GlassScriptPhysician profile
Haider Nurzay
NPI 1992208789
$13,230.99
in general payments reported to CMS, 2019-2025
58 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 93% of Obstetric, Inpatient providers received nationally (typical 2025 total: $94.16).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,071 · 2022: $3,053 · 2023: $3,897 · 2024: $1,476 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,107.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,024.48 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,773.67 | 2021-2025 | |
| Novo Nordisk INC | $701.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.12 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $617.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $615.42 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $512.09 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $475.98 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $448.21 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $427.25 | 2022-2025 | Ingrezza |
| Pfizer INC. | $417.45 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $411.39 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.09 | 2021-2024 | Xifaxan |
| Ardelyx, INC. | $311.76 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $280.90 | 2023-2025 | Cologuard Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haider Nurzay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.